Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non-small cell lung cancer (NSCLC) patients undergoing definitive radiation therapy: Pilot study results

Cancer

Volumn 121, Issue 1, 2015, Pages 139-149

  Dorsey, Jay F ^a   Kao, Gary D ^a   MacArthur, Kelly M ^a   Ju, Melody ^a   Steinmetz, David ^a   Wileyto, E Paul ^b   Simone, Charles B ^a   Hahn, Stephen M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Assay; Biomarkers; Circulating tumor cells; Non small cell lung cancer; Telomerase

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; TELOMERASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; AUTOMATION; BLOOD SAMPLING; CANCER RADIOTHERAPY; CELL ASSAY; CELL COUNT; CELL VIABILITY; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME ACTIVITY; ENZYME ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; MALE; MIDDLE AGED; MOLECULAR IMAGING; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; PILOT STUDY; TREATMENT RESPONSE; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; METABOLISM; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR EMBOLISM;

AGED; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PILOT PROJECTS; TELOMERASE; TREATMENT OUTCOME;

EID: 84918804152     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28975     Document Type: Article

References (35)

1. American Cancer Society. What Are the Key Statistics About Lung Cancer? Atlanta, GA: American Cancer Society; 2013. Available at: http://www.cancer.org/cancer/lungcancer-nonsmallcell/detailedguide/nonsmall-cell-lung-cancer-key-statistics. Updated 2013. Accessed January 8, 2014.
2. Hanley M, Welsh C, eds. Current Diagnosis and Treatment in Pulmonary Medicine. New York: McGraw-Hill; 2003.
3. Takeda A, Kunieda E, Takeda T, et al. Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys. 2008;70:1057-1065.
4. Huang K, Dahele M, Senan S, et al. Radiographic changes after lung stereotactic ablative radiotherapy (SABR)-can we distinguish recurrence from fibrosis? A systematic review of the literature. Radio-ther Oncol. 2012;102:335-342.
5. Dahele M, Palma D, Lagerwaard F, Slotman B, Senan S. Radiological changes after stereotactic radiotherapy for stage I lung cancer. J Thorac Oncol. 2011;6:1221-1228.
6. Van Elmpt W, Pottgen C, De Ruysscher D. Therapy response assessment in radiotherapy of lung cancer. Q J Nucl Med Mol Imaging. 2011;55:648-654.
7. Devriese LA, Bosma AJ, van de Heuvel MM, Heemsbergen W, Voest EE, Schellens JH. Circulating tumor cell detection in advanced nonsmall cell lung cancer patients by multi-marker QPCR analysis. Lung Cancer. 2012;75:242-247.
8. Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10: 6897-6904.
9. Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 2011;29:1556-1563.
10. Hofman V, Bonnetaud C, Ilie MI, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res. 2011;17:827-835.
11. Nieva J, Wendel M, Luttgen MS, et al. High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis [serial online]. Phys Biol. 2012;9:016004.
12. Ge M, Shi D, Wu Q, Wang M, Li L. Fluctuation of circulating tumor cells in patients with lung cancer by real-time fluorescent quantitative-PCR approach before and after radiotherapy. J Cancer Res Ther. 2005;1:221-226.
13. Du YJ, Li J, Zhu WF, et al. Survivin mRNA-circulating tumor cells predict treatment efficacy of chemotherapy and survival for advanced non-small cell lung cancer patients. Tumour Biol. 2014;35:4499-4507.
14. Lim E, Tay A, Von Der Thusen J, Freidin MB, Anikin V, Nicholson AG. Clinical results of microfluidic antibody-independent peripheral blood circulating tumor cell capture for the diagnosis of lung cancer. J Thorac Cardiovasc Surg. 2014;147:1936-1938.
15. Lou J, Ben S, Yang G, et al. Quantification of rare circulating tumor cells in non-small cell lung cancer by ligand-targeted PCR [serial online]. PLoS One. 2013;8:e80458.
16. Huang J, Wang K, Xu J, Huang J, Zhang T. Prognostic significance of circulating tumor cells in non-small-cell lung cancer patients: a meta-analysis [serial online]. PLoS One. 2013;8:e78070.
17. Wang J, Wang K, Xu J, Huang J, Zhang T. Correction: prognostic significance of circulating tumor cells in non-small-cell lung cancer patients: a meta-analysis [serial online]. PLoS One. 2014;9:eb7.
18. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450:1235-1239.
19. Rolle A, Gunzel R, Pachmann U, Willen B, Hoffken K, Pachmann K. Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAIN-TRAC is a predictor for relapse: a preliminary report [serial online]. World J Surg Oncol. 2005;3:18.
20. Wu C, Hao H, Li L, et al. Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients. J Thorac Oncol. 2009;4:30-36.
21. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
22. Kim Y, Kim HS, Cui ZY, et al. Clinicopathological implications of EpCAM expression in adenocarcinoma of the lung. Anticancer Res. 2009;29:1817-1822.
23. Wang X, Qian X, Beitler JJ, et al. Detection of circulating tumor cells in human peripheral blood using surface-enhanced Raman scattering nanoparticles. Cancer Res. 2011;71:1526-1532.
24. Liu Z, Li Q, Li K, et al. Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene. 2013;32:4203-4213.
25. Kim SJ, Masago A, Tamaki Y, et al. A novel approach using telomerase-specific replication-selective adenovirus for detection of circulating tumor cells in breast cancer patients. Breast Cancer Res Treat. 2011;128:765-773.
26. Kojima T, Hashimoto Y, Watanabe Y, et al. A simple biological imaging system for detecting viable human circulating tumor cells. J Clin Invest. 2009;119:3172-3181.
27. Maida Y, Kyo S, Sakaguchi J, et al. Diagnostic potential and limitation of imaging cancer cells in cytological samples using telomerase-specific replicative adenovirus. Int J Oncol. 2009;34:1549-1556.
28. Macarthur KM, Kao GD, Chandrasekaran S, et al. Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay. Cancer Res. 2014;74:2152-2159.
29. Ju M, Kao GD, Steinmetz D, et al. Application of a telomerase-based circulating tumor cell (CTC) assay in bladder cancer patients receiving postoperative radiation therapy: a case study. Cancer Biol Ther. 2014;15:683-687.
30. Williams RL. A note on robust variance estimation for cluster-correlated data. Biometrics. 2000;56:645-646.
31. Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.
32. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011-2015.
33. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997;33:787-791.
34. Gauthier LR, Granotier C, Soria JC, et al. Detection of circulating carcinoma cells by telomerase activity. Br J Cancer. 2001;84:631-635.
35. Han HS, Eom DW, Kim JH, et al. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases. Clin Lung Cancer. 2011;12:380-386.